IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.
"The test kit is posted to you. It comes with everything you need. You take the test and post your sample back. Then you’ll get your results"
It isn't an LFT, it's a lab test.
My understanding is that the restriction as to the use of the machine, was part of the contract. The contract is no longer in place, it expired.
so what follows is either as detailed in the expiry section of the contract, or as a new separately arranged agreement. As i recall the relevant section said HMG would pick up the machinery within a month of expiry. They have not done so. What happens now is to be decided. It is NOT determined by a contract that is dead.
In keeping with many, there is a preference for the uber rampers to stick to Twitter, that way they can just block those that call out their bull or don't pay them due deference, and therefore keep a thread going that apparently everyone agrees with ! They have been talking absolute crap since the start, taking the tinniest bit of information that is extremely tangential to ODX and fabricating it into guaranteed ODX prosperity.
Shredz blocked me after my first reply to him :)
in case you didn't realise it, "99" is Jadam, Harvey etc etc
decoded means..."no he can't show you a link, there isn't any".
Apparently this "early data" is only being shared verbally :)
LOL !
It wasn't useless at all, it gave the CEO and some of the many (MANY) non operational staff something to do over the last couple of weeks.
BUSY...BUSY...
...and not an antibody test in sight to omit those that clearly do not need them....Israel isn't using them...Germany isn't using them.
So much for booster campaigns resulting in the use of antibody testing. Frankly I always thought it was garbage, but it was garbage from the CEO. As we all know, the current booster campaign is getting 800K-1M a day in the UK, and putting a lot of other NHS services on hold. If everyone one of those eligible for a booster had to have a 20min antibody test to determine whether booster was needed or not, it would just be completely impractical, given that a gov wide program would not allow individuals to administer and read the test, therefore would have to be performed onsite by trained personnel.
I think we can file mass government antibody testing anywhere in the world in the bin, some surveillance maybe, but I suggest that for that scenario you want numerical statistics (i.e lab testing) not some line of variations of pink.
Beynon what are you on about ????, both answers that referenced employee head count stated that it was correct as of 30th Nov NOT the date of the interims (30th Sept)
The answer to Q150 is:-
"At 30 NOVEMBER 2021, the Group employed 227 people. In addition, there were 84 agency staff, mostly working on the short term contract for Orient Gene."
The answer to question Q245 is:
"AT 30 NOVEMBER 2021, we employed 106 Operations staff across our two sites, plus an additional 84 agency staff, mostly working on the short term contract for Orient Gene."
You stated something as a fact that a basic check would show was entirely unfactual...did you not bother ?
How many thousands of times over the last year have people stated garbage on here as FACTS, that weren't so easily disproved
The answer to Q150 is:-
"At 30 November 2021, the Group employed 227 people. In addition, there were 84 agency staff, mostly working on the short term contract for Orient Gene."
The answer to question Q245 is:
"At 30 November 2021, we employed 106 Operations staff across our two sites, plus an additional 84 agency staff, mostly working on the short term contract for Orient Gene."
From the above, over half of the employees are NOT operations staff. That seems a lot for a manufacturing company.
In relation to the comments up thread, the recent RNS made it clear they were looking to resize DOWNWARDS. THe audio for question 206 indicates that the OG work will bring in £0.5M, with £0.1M profit.
In general commentary about the Q&A, 1) the "when did you learn that the contract was dead" question was answered about 25-30 times...was that really necessary...and many many other questions were repeats. out of the over 300 questions probably less than 1/2 were unique. 2) I predict the company will stop doing these Q&As in this format.
My questions were Q75,76,77. The answer to Q75 says that Covios approvals have no relevance for visitect...there is no generic piggybacking. The important bits of Q76 (any sign of govs using antibody tests for vaccination selection or part of of booster program like you said in jul) were not answered,
Dj “I am zee maker of zee list and u are on zee list” has no actual contributory benefit other than to see all the people that he is not seeing (wink)
"Twatcher your knowledge of this share and the industry is second to none. I'm guessing you are more than just a shareholder and must be heavily involved in the industry?"
You guess incorrect, I think you may be looking at the various posts on here from many that show that they have really zero knowledge of ODX, and then extrapolating too much from the fact that I tend to stick to fact based posts.
"Twatch -Avacta still got partnership with Mologic?"
No idea, I don't follow AVacta at all, hence why I asked on another thread whether they had manufacturing capability. Surprised that of all those that proport to follow both Avacta and ODX, no one has replied.
"Surely the fact that avacta has reached this milestone means it's likely ODX is close to the same, albeit not nailed on? The melodramatic "weeping" for ODX is unnecessary. "
Why do you think an entirely unassociated test, with unassociated user trials, submitted by an unassociated company via a different notifible body, has any implications whatsoever for visitect approval.
Other than telling you that an approval has happened, i.e. that they are not halted, it tells you nothing of relevance in regard to whether visitect gets approval, or the timeline.
THere are 40+ lfts listed on the FDA EUA list, of which a dozen are for home use.
Why would you think Mologic will get a slice of an order before those, when Mologic has no FDA certification, i.e. it is not authorised in the US.
500M sounds a lot, but UK have order many billions, 99% of which have been just two chinese tests, Innova and flowflex.
Asking for a friend.
a leader would be appreciated.
Question...I assume that even if the visitect test where to get ce/eu home use approval tomorrow, it would still be barred from supply in the UK, until the CTDA approval comes thru ?
I'd welcome options, provided they are exercisable at 60p+
speaking of Colin and the directors, it is an undisputable fact that not a single one of them have seen value in ODX shares at this level....no director has bought shares.
Frankly if the directors don't see value in the SP at this level, having fallen so low, should it be a surprised that the market doesn't either ?
ODX tweet 10-sept "We will of course keep you appraised of the progress of our US FDA Emergency Use Authorisation submission, in conjunction with our partners, Mologic. But is is, without a doubt, a pivotal part of our plan"
"without a doubt"...I queried that at the time, as they had told us in the RNS just a couple of months earlier that the significance of the covid opportunity was reliant on the HMG contract( NOT the US) "COVID-19 antigen testing still remains a significant opportunity for us, although very much dependent on the UK Government's decisions as to test selection and timing. "
Anyhow, the above tweet started a lot of chat about ODX was obviously going to go for home use approval, as it was timed around the same time the biden admin was talking about a massive ramp up in testing. Since then we have had ODX basically say " well we'll take a look at it, but it looks far too expensive to do it", and now that bearer of good news Regulator has seeded (without citation) that the test may failed FDA approval anyway (which means no professional use).
So, yet another brilliantly worded tweet from ODX. They do realise that the nature of a pivot is that it can result in a swing either way ?